Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
The invention provides polymorphs of a compound of Formula (X): The invention also provided pharmaceutical compositions containing polymorphs of the compound and methods treating conditions in a subject by providing polymorphs of the compound.
1. A crystal comprising a Form A polymorph of a monohydrate hydrochloride salt of a compound of Formula (X):
wherein the Form A polymorph has an XRPD pattern as shown in FIG. 4 .
2. The crystal of claim 1 , wherein the crystal is substantially free of polymorphs of Form B, Form C, Form D, and Form E.
3. A pharmaceutical composition comprising a crystal comprising a Form A polymorph of a monohydrate hydrochloride salt of a compound of Formula (X):
wherein the Form A polymorph has an XRPD pattern as shown in FIG. 4 .
4. The composition of claim 3 , wherein the composition is substantially free of polymorphs of Form B, Form C, Form D, and Form E.
5. The composition of claim 3 , wherein the composition is formulated for oral administration.
6. The composition of claim 3 , wherein the composition is formulated as a single unit dosage.
7. The composition of claim 3 , wherein the composition is formulated as divided dosages.
8. A method of treating a condition in a subject, the method comprising providing to a subject having, or at risk of developing, a condition a composition comprising a therapeutically effective amount of a Form A polymorph of a monohydrate hydrochloride salt of a compound of Formula (X):
wherein the Form A polymorph has an XRPD pattern as shown in FIG. 4 , and wherein the condition is selected from the group consisting of aneurysm, angina, atherosclerosis, cardiomyopathy, cerebral vascular disease, congenital heart disease, coronary artery disease, coronary heart disease, diabetic cardiomyopathy, heart attack, heart disease, heart failure, hypertension, ischemic heart disease, pericardial disease, peripheral arterial disease, rheumatic heart disease, stroke, transient ischemic attacks, and valvular heart disease.
9. The method of claim 8 , wherein the composition is provided orally.
10. The method of claim 8 , wherein the composition is provided as a single unit dosage.
11. The crystal of claim 1 , wherein the compound has an endothermic peak at about 85.3° C. (±5° C.) and at about 214.6° C. (±5° C.) in a differential scanning calorimetry (DSC) thermogram.
12. The crystal of claim 11 , wherein the compound has a DSC thermogram substantially in accordance with FIG. 5 .
13. The crystal of claim 1 , wherein the compound exhibits a dehydration at about 25.9° C. to about 150.0° C. with a weight loss of about 3.46% in a thermogravimetric analysis (TGA).
14. The crystal of claim 1 , wherein the compound has a TGA thermogram substantially in accordance with FIG. 5 .
15. The composition of claim 3 , wherein the compound has an endothermic peak at about 85.3° C. (±5° C.) and at about 214.6° C. (±5° C.) in a differential scanning calorimetry (DSC) thermogram.
16. The composition of claim 15 , wherein the compound has a DSC thermogram substantially in accordance with FIG. 5 .
17. The composition of claim 3 , wherein the compound exhibits a dehydration at about 25.9° C. to about 150.0° C. with a weight loss of about 3.46% in a thermogravimetric analysis (TGA).
18. The composition of claim 3 , wherein the compound has a TGA thermogram substantially in accordance with FIG. 5 .
19. The method of claim 8 , wherein the compound has an endothermic peak at about 85.3° C. (±5° C.) and at about 214.6° C. (±5° C.) in a differential scanning calorimetry (DSC) thermogram.
20. The method of claim 19 , wherein the compound has a DSC thermogram substantially in accordance with FIG. 5 .
21. The method of claim 8 , wherein the compound exhibits a dehydration at about 25.9° C. to about 150.0° C. with a weight loss of about 3.46% in a thermogravimetric analysis (TGA).
22. The method of claim 8 , wherein the compound has a TGA thermogram substantially in accordance with FIG. 5 .